Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02380274 · ClinicalTrials.gov registry record
Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)
A clinical trial, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- 1,030
- Enrollment target
NCT02380274: Completed study, sponsored by Astellas Pharma Global Development.
NCT02380274 is a clinical trial that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 1,030 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02380274 has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- 1,030 participants
- Enrollment target
Study Summary
The purpose of this study is to describe patterns of care in CRPC patients, as well as health-related quality of life (HRQoL) outcomes associated with CRPC and its management. This study will also describe factors influencing treatment decisions including reason(s) for treatment choices and triggers for treatment changes for CRPC as well as describe clinical outcomes based on patient characteristics.
Primary Outcome
Treatment patterns will be described according to: The distribution and timing of disease assessment methods (PSA, other laboratory testing, imaging); Treatment settings; Physician referral patterns from urologist to oncologist (occurrence and timing of referrals) where applicable; CRPC treatments, including initial choices, sequencing and entry into interventional clinical trials
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,030 participants |
| Start Date | 2015-03-27 |
| Est. Completion | 2021-01-14 |
What the finished NCT02380274 record still lists
NCT02380274 is an observational study that tracks outcomes without assigning an intervention. Its 1,030 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02380274 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02380274 about?
NCT02380274 is a clinical study titled "Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)". The purpose of this study is to describe patterns of care in CRPC patients, as well as health-related quality of life (HRQoL) outcomes associated with CRPC and its management. This study will also describe factors influencing treatment decisions including reason(s) for treatment choices and trigger...
What is the current status of trial NCT02380274?
This trial is currently completed. The enrollment target is 1,030 participants. The study started on 2015-03-27. Estimated completion is 2021-01-14.
Who is sponsoring clinical trial NCT02380274?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06080698 · 1,030 participants · NA
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
- NCT07084363 · 1,032 participants · NA
Quantitative Versus qUAlitative NeuromoniToring of neUroMuscular Block for Non-cardiothoracic Surgery
- NCT05037682 · 1,035 participants · NA
Pain and Opioid Management in Older Adults
- NCT07282600 · 1,035 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI